Stock PTGX PROTAGONIST THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
34.59 USD -1.73% Intraday chart for Protagonist Therapeutics, Inc. +9.08% +50.85%
12:00am Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000 CI
12:00am Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000
CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care
CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P Composite 1500
CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600
CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 3000E Value Index
CI
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024
AQ
Protagonist Therapeutics to Join S&P SmallCap 600
MT
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
AQ
Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control
CI
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing
MT
Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing
MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Protagonist Therapeutics: Q1 Earnings Snapshot
AQ
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing
MT
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
AQ
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data
CI
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
CI
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study
MT
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis
CI
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PTGX Stock
  4. News Protagonist Therapeutics, Inc.